文献速递胸部肿瘤放疗放疗物理与技术

胸部再程立体定向体部放疗治疗既往高剂量照射野内或紧邻区域残留/复发及新发原发非小细胞肺癌

Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field.
PubMed 文献 · Pract Radiat Oncol · 2017-12-08

本研究回顾性分析72例在既往高剂量外照射或SBRT野内或紧邻区域接受SBRT再程治疗的残留、局部复发或新发原发非小细胞肺癌患者。中位随访17.9个月,中位总生存20.8个月,2年局部失败率21.6%,无治疗相关死亡。SBRT似乎是安全有效的 salvage 手段。

要点

  • 再程SBRT后中位总生存20.8个月,2年局部失败率21.6%,无治疗相关死亡。
  • 再程SBRT前SUVmax低于中位(<7.0)者2年局部控制93.1% vs 高于中位者61.1%(P<.001)。
  • 新发原发者2年远处转移率10.4% vs 残留/复发者54.1%(P<.001)。

核心结论

  • SBRT似乎是挽救既往高剂量照射野内或紧邻区域残留、复发或新发原发非小细胞肺癌的安全有效手段。

研究设计与样本

  • 回顾性分析本机构72例因残留、局部复发或新发原发非小细胞肺癌在既往高剂量外照射或SBRT野内或紧邻区域接受SBRT再程治疗的患者,采用Kaplan-Meier分析和log-rank检验估计终点并比较队列。

主要发现

  • 中位随访17.9个月;残留或复发患者占54.2%,新发肺部原发占45.8%。
  • 再程照射靶区T中位大小2.5 cm(范围0.8-7.8 cm),再程治疗前中位SUVmax为7.15(范围1.2-37.6)。
  • 最常见SBRT再程方案为48 Gy分4次(范围17-60 Gy分1-5次);中位无进展生存15.2个月,中位总生存20.8个月,2年局部失败率21.6%。
  • 再程照射时SUVmax<7.0者2年局部控制率93.1% vs 高于中位者61.1%(P<.001)。
  • 新发原发者2年远处转移率10.4% vs 残留或复发者54.1%(P<.001);中位无进展生存31.9个月 vs 8.4个月(P=.037);中位生存25.2个月 vs 16.2个月(P=.049);再程SUVmax低于中位者中位生存42.0个月 vs 高于中位者9.8个月(P<.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Local failure following concurrent chemoradiation and in-lobe failures following stereotactic body radiation therapy (SBRT) are common. We evaluated our institutional experience using SBRT as salvage in this setting. METHODS AND MATERIALS: Seventy-two patients were reirradiated with SBRT for residual, locally recurrent, or new primary non-small cell lung cancer within or adjacent to a high-dose external beam radiation therapy or SBRT field. Kaplan-Meier analysis with log-rank test were used to estimate endpoints and differentiate cohorts. RESULTS: Median follow-up was 17.9 months. Patients had residual or recurrent disease (54.2%); 45.8% had new lung primaries. Median reirradiated T size was 2.5 cm (range, 0.8-7.8 cm). Median pre-retreatment maximum standardized uptake value (SUVmax) was 7.15 (range, 1.2-37.6). The most common SBRT reirradiation regimen was 48 Gy in 4 fractions (range, 17-60 Gy in 1-5 fractions). Median progression-free survival was 15.2 months, and median overall survival was 20.8 months. Two-year local failure was 21.6%. Patients with SUVmax at reirradiation <7.0 had a 2-year local control of 93.1% versus 61.1% above the median (P < .001). The 2-year rate of distant metastases was 10.4% versus 54.1% in patients treated for a new primary versus residual or recurrent disease (P < .001). Median progression-free survival was 31.9 months versus 8.4 months, respectively (P = .037). Median survival of patients treated for new primary was 25.2 months versus 16.2 months with residual or recurrent disease (P = .049), and median survival for patients with reirradiation SUVmax below the median was 42.0 months versus 9.8 months above the median (P < .001). Acute any-grade toxicity was seen in 29.2% of patients, acute grade 3 toxicity in 11.1%, and late grade 3 toxicity in 1.4% with no treatment-related deaths. CONCLUSIONS: SBRT appears to be a safe and effective means of salvaging recurrent, residual, or new primary NSCLC in or adjacent to a previous high-dose radiation field.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Horne ZD, Dohopolski MJ, Clump DA, et al. Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field. Pract Radiat Oncol. 2017. PMID: 29724402. doi:10.1016/j.prro.2017.11.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。